O	0	10	Prevention
O	11	13	of
B-condition	14	26	chemotherapy
I-condition	26	27	-
I-condition	27	34	induced
I-condition	35	45	peripheral
I-condition	46	56	neuropathy
O	57	61	with
B-intervention	62	71	classical
I-intervention	72	79	massage
O	80	82	in
B-eligibility	83	89	breast
I-eligibility	90	96	cancer
I-eligibility	97	105	patients
I-eligibility	106	115	receiving
I-eligibility	116	126	paclitaxel
O	126	127	:
O	128	130	An
O	131	139	assessor
O	139	140	-
O	140	147	blinded
O	148	158	randomized
O	159	169	controlled
O	170	175	trial
O	175	176	.

O	177	181	This
O	182	190	assessor
O	190	191	-
O	191	198	blinded
O	198	199	,
O	200	211	prospective
O	211	212	,
O	213	223	randomized
O	224	234	controlled
O	235	243	clinical
O	244	249	trial
O	250	255	aimed
O	256	258	at
O	259	272	investigating
O	273	276	the
O	277	283	effect
O	284	286	of
O	287	296	classical
O	297	304	massage
O	305	307	on
O	308	320	chemotherapy
O	321	328	induced
O	329	339	peripheral
O	340	350	neuropathy
O	351	354	and
O	355	358	the
O	359	366	quality
O	367	369	of
O	370	374	life
O	375	376	(
O	376	379	QOL
O	379	380	)
O	381	383	in
O	384	390	breast
O	391	397	cancer
O	398	406	patients
O	407	416	receiving
O	417	425	adjuvant
O	426	436	paclitaxel
O	436	437	.

O	438	439	A
O	440	445	total
O	446	448	of
B-total-participants	449	451	40
O	452	458	female
O	459	465	breast
O	466	472	cancer
O	473	481	patients
O	482	486	were
O	487	495	randomly
O	496	505	allocated
O	506	508	to
O	509	512	the
O	513	522	classical
O	523	530	massage
O	531	536	group
O	537	538	(
O	538	541	CMG
O	541	542	)
O	543	545	or
O	546	549	the
B-control	550	557	control
I-control	558	563	group
I-control	564	565	(
I-control	565	567	CG
I-control	567	568	)
O	568	569	.

O	570	579	Classical
O	580	587	massage
O	588	591	was
O	592	599	applied
O	600	602	to
O	603	606	the
O	607	615	patients
O	616	618	in
O	619	622	the
O	623	626	CMG
O	627	633	before
O	634	638	each
O	639	649	paclitaxel
O	650	658	infusion
O	658	659	.

O	660	663	The
O	664	666	CG
O	667	675	received
O	676	680	only
O	681	686	usual
O	687	691	care
O	691	692	.

O	693	701	Presence
O	702	704	of
O	705	715	peripheral
O	716	727	neuropathic
O	728	732	pain
O	733	736	and
O	737	740	QOL
O	741	745	were
O	746	754	assessed
O	755	757	at
O	758	766	baseline
O	767	770	and
O	771	776	weeks
O	777	778	4
O	778	779	,
O	780	781	8
O	781	782	,
O	783	785	12
O	785	786	,
O	787	790	and
O	791	793	16
O	793	794	.

O	795	800	Nerve
O	801	811	conduction
O	812	819	studies
O	820	821	(
O	821	824	NCS
O	824	825	)
O	826	834	findings
O	835	839	were
O	840	844	also
O	845	853	recorded
O	854	856	at
O	857	865	baseline
O	866	869	and
O	870	874	week
O	875	877	12
O	877	878	.

O	879	882	The
B-outcome	883	893	peripheral
I-outcome	894	905	neuropathic
I-outcome	906	910	pain
O	911	914	was
O	915	920	lower
O	921	923	in
O	924	927	the
O	928	931	CMG
O	932	940	compared
O	941	943	to
O	944	947	the
O	948	950	CG
O	951	953	at
O	954	958	week
O	959	961	12
O	962	963	(
O	963	964	p
O	965	966	<
O	967	968	0
O	968	969	.
O	969	971	05
O	971	972	)
O	972	973	.

O	974	977	The
B-outcome	978	985	sensory
I-outcome	986	989	and
I-outcome	990	995	motor
I-outcome	996	999	sub
I-outcome	999	1000	-
I-outcome	1000	1005	scale
I-outcome	1006	1012	scores
I-outcome	1013	1015	of
I-outcome	1016	1019	the
I-outcome	1020	1023	QOL
O	1024	1031	measure
O	1032	1038	showed
O	1039	1052	statistically
O	1053	1064	significant
O	1065	1076	differences
O	1077	1081	over
O	1082	1086	time
O	1087	1089	in
O	1090	1095	favor
O	1096	1098	of
O	1099	1102	the
O	1103	1106	CMG
O	1107	1108	(
O	1108	1109	p
O	1110	1111	<
O	1112	1113	0
O	1113	1114	.
O	1114	1116	05
O	1116	1117	)
O	1117	1118	.

B-outcome	1119	1126	Sensory
I-outcome	1127	1133	action
I-outcome	1134	1143	potential
I-outcome	1144	1153	amplitude
I-outcome	1154	1156	of
I-outcome	1157	1160	the
I-outcome	1161	1167	median
I-outcome	1168	1173	nerve
O	1174	1177	was
O	1178	1191	significantly
O	1192	1198	higher
O	1199	1202	and
O	1203	1206	the
O	1207	1213	tibial
O	1214	1219	nerve
O	1220	1227	latency
O	1228	1231	was
O	1232	1245	significantly
O	1246	1253	shorter
O	1254	1256	in
O	1257	1260	the
O	1261	1264	CMG
O	1265	1273	compared
O	1274	1276	to
O	1277	1280	the
O	1281	1283	CG
O	1284	1286	at
O	1287	1291	week
O	1292	1294	12
O	1294	1295	.

O	1296	1300	This
O	1301	1306	study
O	1307	1316	suggested
O	1317	1321	that
O	1322	1331	classical
O	1332	1339	massage
O	1340	1352	successfully
O	1353	1362	prevented
O	1363	1375	chemotherapy
O	1375	1376	-
O	1376	1383	induced
O	1384	1394	peripheral
O	1395	1406	neuropathic
O	1407	1411	pain
O	1411	1412	,
O	1413	1421	improved
O	1422	1425	the
O	1426	1429	QOL
O	1429	1430	,
O	1431	1434	and
O	1435	1441	showed
O	1442	1452	beneficial
O	1453	1460	effects
O	1461	1463	on
O	1464	1467	the
O	1468	1471	NCS
O	1472	1480	findings
O	1480	1481	.
